STOCK TITAN

Shareholder in OCUL (NASDAQ: OCUL) plans 4,408-share sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 shows that Steve Meyers has filed a notice of intent to sell 4,408 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate aggregate market value of $37,636.39. The issuer has 213,047,472 shares outstanding.

The shares to be sold come from restricted stock vesting under a registered plan on 02/03/2026, acquired directly from the issuer. In the prior three months, Meyers sold 3,052 common shares for $27,903.83. The filer represents they know no undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for OCUL disclose about planned share sales?

The filing shows Steve Meyers plans to sell 4,408 common shares of OCUL through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $37,636.39. This is a notice of proposed sales under Rule 144, not a confirmation of completion.

How many OCUL shares are outstanding in the Form 144 notice?

The Form 144 states that the issuer has 213,047,472 common shares outstanding. This figure provides context for the planned sale of 4,408 shares, indicating the notice relates to a very small portion of the company’s total outstanding stock at the time referenced.

How were the OCUL shares in the Form 144 acquired by the seller?

The filing explains the 4,408 OCUL common shares were acquired on 02/03/2026 as restricted stock vesting under a registered plan from the issuer. The nature of payment is listed as “Not Applicable,” reflecting that this was an equity award vesting rather than a cash purchase.

What prior OCUL share sales are disclosed in the last three months?

The Form 144 reports that Steve Meyers previously sold 3,052 OCUL common shares on 02/02/2026, generating $27,903.83 in gross proceeds. This historical sale information is required to be aggregated with the new planned sale under Rule 144 reporting rules.

Which broker and exchange are involved in the OCUL Form 144 sale?

The notice lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, as the broker handling the proposed sale of 4,408 OCUL common shares. The securities are planned to be sold on the NASDAQ stock market, according to the filing.

What representation does the seller make in the OCUL Form 144 filing?

By signing the notice, the seller represents they do not know any material adverse information about OCUL’s current or prospective operations that has not been publicly disclosed. This representation is a standard requirement when filing planned sales under Rule 144.
Ocular Therapeut

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

1.82B
206.17M
3.33%
90.81%
7.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD